TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number AEs Related to Atezolizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Progression of radiographs joint damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disease activity remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical and mental health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reflection-Impulsivity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evaluation of duct patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fugl Meyer Lower Limb Balance Assessment Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Smartphone Addiction Scale -Short Version (SAS-SV)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean value of self-measured blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of patients with primary immunodeficiency revealed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in pain during activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 week continue quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Task-functional connectivity from functional magnetic resonance imaging (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cigarette per day
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Kessler 6 Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient Health Questionnaire - 9 (PHQ-9) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child and Adolescent Trauma Screen (CATS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary patency of stent at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite of major adverse events (MAEs) up to 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any Serious Adverse Event (SAE) related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any Grade 3 or higher AEs related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fetal diffusion parameters: fractional anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fetal diffusion parameters: mean diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety and need for information
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with the preparation process for surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: acceptability of caregiver-assisted oral fluid-based HIV screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: feasibility of caregiver-assisted oral fluid-based HIV screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: effectiveness of caregiver-assisted oral fluid-based HIV screening on testing yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to weight-focused health coaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to weight-neutral health coaching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Health Impact Profile (OHIP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased Kinesiophobia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to successful endotracheal tube insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC/MIC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ctrough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of complete wound healing of the ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of absence of major amputation
Endpoint domain: Mortality/survival
Primary endpoint: association with phenotypic manifestation of PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in IGFR1 levels in keloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Bone Turnover/Cell Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Systemic Inflammation - Serum/Plasma Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic inflammation - Immune Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Standard Uptake Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QRS width changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tpe interval changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MBG during PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the Tablet Routine Questionnaire (TRQ) past week item at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in the Tablet Routine Questionnaire (TRQ) past month item at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in treatment adherence as measured by electronic pill monitoring (eCAPS) at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of carbapenemase gene types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to first hospitalization for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first hospitalization for myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first hospitalization for ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to incident or worsening nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Capability of vaginal and/or anal penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oncologic tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: [177Lu]Lu-BQ7876 blood clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gamma camera-based whole-body [177Lu]Lu-BQ7876
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT/CT-based [177Lu]Lu-BQ7876 uptake in tumor lesions (SUVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute GU toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome of PNNJ in neonates and children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reach of HCC screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Reach of CRC screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean weekly adherence to controller medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) up to Time t (AUC0-t) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Infinity (AUC0-inf) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rate of gastric ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quantification of Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Time in Glucose target range (4-10 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c level in control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in periodic limb movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Restless Legs Syndrome symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Cone Beam Computed Tomography Periapical Index (CBCTPAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of periapical index (PAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of modified wound healing scale (Mod-CWHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of pain severity in 0-10 pain severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Day 2 of research subject's thoughts on treatment result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients free of clinically relevant skin toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Pain related to laser follicle ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events occurred during clinical trials
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects Achieving EASI-75 Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success of office hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Laparoscopic entry time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Usability of retinal and choroidal vascularization acquisitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neck (Cervical) Proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision-Matched Treatment Utilization Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive Brain Region Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced At Least One AE
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response Rate (CRR) per Lugano Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of the epileptogenic zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: c-telopeptide of type I collagen (CTX) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Type 1 inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Type 2 inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Innate immune inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in epithelial barrier function protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in epithelial integrity markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung cancer screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Seizures Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Seizures Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of Life level
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Breastfeeding Charting System: LATCH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inadequate Milk Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PROMIS anxiety measure score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of adverse events attributable to kava
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome of healthcare contacts for depressed patients before the digital healthcare platform
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Outcome of healthcare contacts for depressed patients after the digital healthcare platform
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Staff-reported well-being in digital healthcare compared to traditional healthcare work
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual analogue Score (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Facial Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Thai MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Minimal Residual Disease Negative Complete Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of Kintsugi Voice Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in CLASI-A Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glenohumeral internal rotation deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the P. vivax IBSM model
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of fungal infection
Endpoint domain: Adverse events/effects
Primary endpoint: Orientation discrimination threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptual Confidence in Orientation Discrimination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Labor outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Continuous monitoring of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of POCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinical and pathological complete response (cCR/pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of combined platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time Zero to Time of the Last Measurable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular and cellular characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Targeted Adverse Events (TAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in levels of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weighted Adverse Outcome Score (WAOS)
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammation status by inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammation status by high-sensitive CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of Type II Diabetes Mellitus
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in frequency of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in vital sign measurements - blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N-Back working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness rate after 6 months' treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquired capability for suicide
Endpoint domain: Adverse events/effects
Primary endpoint: Conspicuities and diagnostic confidence scores for a given lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients achieving complete reversal of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The time for complete reversal of HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluating the efficacy of nifuroxazide in improving mental status by calculating CHESS score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs) at week 4
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with changes to clinical laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent Postmastectomy Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain outcomes
Primary endpoint: ΔCmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ΔAUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ΔAUC0-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily Living Skills Change Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pervasive Developmental Disorders Behavioral Inventory T Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized peak early diastolic filling rate (E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self Reported health survey for Heart Failure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival to discharge from neonatal care
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline depression immediately after the interventions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline depression six months after the interventions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline anxiety immediately after the interventions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline anxiety at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tooth displacement in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest wall pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Analysis on Flat Ground
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait analysis on Perturbed Ground
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with NIHSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Range of Motion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Continuous metabolic syndrome z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dispensation of HPV vaccines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in pre and postoperative value of base excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic gait stability during slip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning and Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HbA1c percent time in control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes